Alembic Pharmaceuticals · NSE: APLLTD · BSE: 533573

Q1 FY27 results · Apr–Jun 2026

Alembic Pharmaceuticals reported revenue from operations of ₹2,149.77 crore (up 25.7% from Q1 FY26) and net profit of ₹172.36 crore (up 12.2% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	2,149.77	1,710.72	+25.7%	1,847.72	+16.3%
Other income	14.93	6.50	+129.7%	25.50	−41.5%
Total income	2,164.70	1,717.22	+26.1%	1,873.22	+15.6%
Profit before share of associates & JVs and tax	221.47	190.55	+16.2%	117.52	+88.5%
Share of profit/(loss) of associates & JVs	0.39	(0.45)		1.11
Net profit for the period	172.36	153.63	+12.2%	201.54	−14.5%
Attributable to shareholders of the company	173.07	154.38	+12.1%	—	—
EPS, basic (₹)	8.80	7.85	+12.1%	10.31	−14.6%
Net margin (%)	8.0	9.0		10.9

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY27	Q1 FY26	YoY	Q4 FY26	QoQ
Revenue from operations	1,868.06	1,494.17	+25.0%	1,718.74	+8.7%
Other income	14.04	7.79	+80.2%	25.88	−45.7%
Total income	1,882.10	1,501.96	+25.3%	1,744.62	+7.9%
Profit before tax	255.90	125.52	+103.9%	173.46	+47.5%
Net profit for the period	196.96	103.52	+90.3%	243.07	−19.0%
EPS, basic (₹)	10.02	5.27	+90.1%	12.37	−19.0%
Net margin (%)	10.5	6.9		14.1

Consolidated

Filed with BSE: 04 Aug 2026, 16:20 IST
Board meeting: 04 Aug 2026
Period: 01 Apr 2026 to 30 Jun 2026
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 04 Aug 2026, 16:20 IST
Board meeting: 04 Aug 2026
Period: 01 Apr 2026 to 30 Jun 2026
Review status: Unaudited
Source: XBRL filing on BSE